This section provides recent updates in the scientific literature that are of interest to patients with diabetes and obesity. The information will touch on diabetes management and newer findings related to the causes and prevention, as well as treatment of obesity.
In Denmark, Weight Loss Drugs Are Reshaping the Economy
By: Eshe Nelson
Published: Aug. 28, 2023, 2:25 p.m. ET
Summary:
This NY Times article describes the extraordinary impact of new weight loss medication on patients with Type 2 Diabetes that is poorly controlled. They are also effective in the treatment of obesity at all levels and this has created a demand that has outstripped supply.
…………………………………………………………………………………………………………
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Prof Filip K Knop et al. The Lancet.
Published: June 25, 2023
Summary:
Significance of this study:
This research demonstrates that overweight or obese adults without type 2 diabetes given 50 mg of semaglutide once a day by mouth lost significant weight of at least 5% in 85% of participants. More than two thirds had lost 10% and one third had lost at least 20% more than placebo. The results were also associated with improvements in cardiometabolic risk factors, compared to the placebo group. The findings were consistent with previous studies with subcutaneous (injections) semaglutide in obesity and with GLP-1 receptor agonists.
Implications:
Oral semaglutide 50 mg might represent an effective option for the treatment of obesity.
…………………………………………………………………………………………………………
BLANK SPACE
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
Vanita R Aroda et al. The Lancet.
Published: June 25, 2023
Summary:
Significance of this study:
The PIONEER PLUS study in adult patients with inadequately controlled type 2 diabetes showed that higher doses of oral semaglutide (25 and 50 mg once daily) resulted in improved blood glucose control compared to previously approved dose of 14 mg once daily. There was also greater reductions in body weight and hemaglobin A1C. The higher doses were well tolerated, although gastrointestinal adverse events were increased with dose escalation. There were no safety concerns with the dose escalation.
Implications:
Adults with sub-optimally controlled type 2 diabetes mellitus given higher doses of semaglutide (25 and 50 mg) once daily provided more effective blood glucose control and weight loss than 14 mg semaglutide without safety concerns.
drtc.ca 